Facebook tracking Pixel


Terrence Dahl Terrence C. Dahl, PhD
BS ’77, Pharmacy
2019 Alumni Achievement Award
The Alumni Achievement Award is presented to an individual who has achieved distinction in their professional field.

Dr. Terrence Dahl is the senior vice president of commercial manufacturing operations at Gilead Sciences, Inc., a research-based biopharmaceutical company focused on the discovery development and commercialization of innovative medicines.

Growing up in Hettinger, North Dakota, Doctor Dahl always had an interest in science and math, which led him to NDSU where he received a bachelor’s degree in pharmacy in 1977. While working toward his doctorate in pharmaceutics at the University of Iowa, Dr. Dahl accepted a summer internship with global biopharmaceutical company Bristol Myers Squibb in New Jersey. The internship became a milestone in his career path and led to his first of several scientific publications.

After earning his Ph.D., Dr. Dahl worked for 12 years as a drug product research scientist at Syntex Laboratories in Palo Alto, Calif. In 1995, he accepted a senior research position at Gilead Sciences, Inc. in California’s Bay Area.

Dr. Dahl still works at Gilead Sciences today where he has risen through the ranks to become senior vice president of commercial manufacturing operations. From the company’s headquarters in Foster City, Calif., he leads a team of more than 700 professionals who oversee the contract manufacturing, packaging and labeling of medicine products throughout North America, Europe and Australia. He also oversees teams at internal sites responsible for sterile and tablet manufacturing as well as packaging facilities in California and in Cork, Ireland.

Since joining Gilead Sciences, Dr. Dahl has worked to either develop or commercialize nearly every product that the company has brought to the worldwide commercial market. He has played an integral part in either the formulation development or commercial manufacturing of leading treatments for the hepatitis B virus, hepatitis C virus, HIV, as well as other diseases.

In 2006, Dr. Dahl helped Gilead Sciences develop the first once-a-day, single-tablet regimen to treat HIV. The single-tablet regimen, containing three drugs, was a scientific breakthrough in the treatment of HIV. His team also led the company’s commercial manufacturing efforts and rapid launch of medications that offer a cure for hepatitis C.

Under Doctor Dahl’s leadership, Gilead Sciences delivers more than 650 million unit doses of medicines to patients worldwide each year and a portfolio of products that generate more than $22 billion in annual revenue. As part of his research, he has authored about 20 scientific publications and he holds more than 10 pharmaceutical patents. In 2015, he received the University of Iowa, College of Pharmacy Distinguished Alumni Award.

Dr. Dahl and his wife, Donna, enjoy traveling the world and attending World Track and Field championships. They live in Sunnyvale, Calif.

NDSU Foundation - Facebook NDSU Foundation - Twitter NDSU Foundation - Instagram NDSU Foundation - Instagram

NDSU Foundation | 1241 North University Drive | PO Box 5144 | Fargo, ND 58102 | 800-279-8971 or 701-231-6800 | Fax: 701-231-6801 | office@ndsufoundation.com

The NDSU Foundation is a nonprofit, tax-exempt charitable organization under Section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law.
Federal Tax ID: 23-7120898